+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Malaria - Pipeline Review, H2 2019

  • ID: 4894155
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 383 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 4SC AG
  • Cadila Healthcare Ltd
  • DMG Deutsche Malaria GmbH
  • ID Pharma Co Ltd
  • Merck KGaA
  • Q BioMed Inc
  • MORE
Malaria - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Malaria - Pipeline Review, H2 2019, provides an overview of the Malaria (Infectious Disease) pipeline landscape.

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Malaria - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 14, 17, 53, 21 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 16, 41 and 32 molecules, respectively.

Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4SC AG
  • Cadila Healthcare Ltd
  • DMG Deutsche Malaria GmbH
  • ID Pharma Co Ltd
  • Merck KGaA
  • Q BioMed Inc
  • MORE
Introduction
Malaria - Overview
Malaria - Therapeutics Development
Malaria - Therapeutics Assessment
Malaria - Companies Involved in Therapeutics Development
Malaria - Drug Profiles
Malaria - Dormant Projects
Malaria - Discontinued Products
Malaria - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Malaria, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Malaria - Pipeline by 4SC AG, H2 2019
Malaria - Dormant Projects, H2 2019
Malaria - Discontinued Products, H2 2019
Malaria - Discontinued Products, H2 2019 (Contd..1), H2 2019

List of Figures
Number of Products under Development for Malaria, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4SC AG
  • AbbVie Inc
  • AdaptVac ApS
  • Akshaya Bio Inc
  • AlfaSigma SpA
  • Allergy Therapeutics Plc
  • Altimmune Inc
  • Artemis Therapeutics Inc
  • Artificial Cell Technologies Inc
  • AUM LifeTech Inc
  • Avalia Immunotherapies Ltd
  • Bharat Biotech Ltd
  • Brain-Gen LLC
  • Cadila Healthcare Ltd
  • Carna Biosciences Inc
  • Cascade Therapeutics Inc
  • CEL-SCI Corp
  • Celgene Corp
  • Cellics Therapeutics Inc
  • Cesa Alliance SA
  • Cilian AG
  • Curevac AG
  • Daiichi Sankyo Co Ltd
  • DesignMedix Inc
  • DMG Deutsche Malaria GmbH
  • Ebelle Pharmaceuticals Inc
  • Eisai Co Ltd
  • ElSohly Laboratories Inc
  • EpicentRx Inc
  • EpiVax Inc
  • Etna Biotech Srl
  • Evotec SE
  • Expres2ion Biotechnologies ApS
  • Fox Chase Chemical Diversity Center Inc
  • GeoVax Labs Inc
  • GlaxoSmithKline Plc
  • Hawaii Biotech Inc
  • Ichor Medical Systems Inc
  • ID Pharma Co Ltd
  • Immtech Pharmaceuticals Inc
  • Immune Modulation Inc
  • Imutex Ltd
  • IMV Inc
  • Innovex Therapeutics SL
  • IPCA Laboratories Ltd
  • Jacobus Pharmaceutical Co Inc
  • Kymab Ltd
  • La Jolla Pharmaceutical Company
  • LondonPharma Ltd
  • Lumen Bioscience Inc
  • Lyndra Inc
  • MediSynergics LLC
  • Merck KGaA
  • Microbiotix Inc
  • Mitsubishi Tanabe Pharma Corp
  • Mycosynthetix Inc
  • Mymetics Corp
  • Nobelpharma Co Ltd
  • Novartis AG
  • Osivax SAS
  • Otsuka Holdings Co Ltd
  • Pacific Meniuoke Biopharmaceutical Company
  • Pfizer Inc
  • Precigen Inc
  • Protein Potential LLC
  • Q BioMed Inc
  • Radix Pharmaceuticals Inc
  • Rodos BioTarget GmbH
  • Sanaria Inc
  • Sanofi
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd
  • Shin Poong Pharm Co Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Theravectys SA
  • Titan Pharmaceuticals Inc
  • Vac4All SAS
  • Vir Biotechnology Inc
  • VLP Biotech Inc
  • VLP Therapeutics LLC
Note: Product cover images may vary from those shown
Adroll
adroll